These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33405993)

  • 41. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
    Wu LS; Hu Y; Gane EJ; Slaets L; De Creus A; Ding Y; Niu J; Schwabe C; Goeyvaerts N; Xu Z; Huo D; Tuefferd M; Verbrugge I; Van Remoortere P; Schwertschlag U; Vandenbossche J
    Antivir Ther; 2023 Feb; 28(1):13596535231151626. PubMed ID: 36691849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
    Boonstra A; Liu BS; Groothuismink ZM; Bergmann JF; de Bruijne J; Hotho DM; Hansen BE; van Vliet AA; van de Wetering de Rooij J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Reesink HW; de Knegt RJ; Janssen HL
    Antivir Ther; 2012; 17(4):657-67. PubMed ID: 22301364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
    Matsuno K; Kuroda S; Tanaka S; Nakamichi H; Kagawa T; Koumura E
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):607-614. PubMed ID: 29845723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
    Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
    J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.
    Parasrampuria DA; de Boer P; Desai-Krieger D; Chow AT; Jones CR
    J Clin Pharmacol; 2003 Apr; 43(4):406-13. PubMed ID: 12723461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects.
    Zhao Y; Xie L; Ou N; Wu J; Zhang H; Zhou S; Liu Y; Chen J; Wang L; Wang L; Wang J; Shao F
    Xenobiotica; 2021 Mar; 51(3):297-306. PubMed ID: 33331206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
    Lawitz E; Rodriguez-Torres M; Denning JM; Albanis E; Cornpropst M; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1209-17. PubMed ID: 23263000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
    Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
    CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M
    Bakker C; Tasker T; Liptrot J; Hart EP; Klaassen ES; Doll RJ; Brown GA; Brown A; Congreve M; Weir M; Marshall FH; Cross DM; Groeneveld GJ; Nathan PJ
    Alzheimers Res Ther; 2021 Apr; 13(1):87. PubMed ID: 33883008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
    Denning J; Cornpropst M; Flach SD; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1201-8. PubMed ID: 23262999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
    Chen H; Chen W; Li H; Xu H; Yuan F; Sheng L; Liu C; Lin P; Yang M; Li X; Liu Y; Walker BM; Gheyas F; Iwamoto M; Stoch SA; Krishna R
    Adv Ther; 2021 Jul; 38(7):3973-3985. PubMed ID: 34101144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.
    Klaus B; Sachse R; Ammer N; Kelepouris N; Ostrow V
    Growth Horm IGF Res; 2020 Jun; 52():101321. PubMed ID: 32325373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.